10 years, the compound growth rate of Chinese herbal pieces is as high as 26%. We predict that the scale of Chinese herbal pieces industry will reach 270 billion yuan in 20 18, but the industry is scattered. As a leading market in the industry, the company's market share is only 3%. We judge that the industry concentration will continue to increase in the future. The company entered the Chinese herbal medicine market in 2002 and is one of the earliest manufacturers in China to enter the Chinese herbal medicine industry. At present, the company has 1 1 production bases in Guangdong, Beijing, Jilin, Sichuan, Anhui and other places, with a complete range of products. At present, it can produce more than 1000 categories and more than 20000 product specifications.
Market scale of Chinese herbal pieces (100 million yuan) 2007-20 18E
According to the latest data from the Ministry of Industry and Information Technology, in the first half of 20 17, the income of Chinese herbal pieces processing industry grew the fastest, increasing by 2 1.33% year-on-year, and the output value reached 104788 billion yuan, which was only lower than that of biopharmaceutical manufacturing. During the ten years from 2006 to 2065438+06, the average growth rate of Chinese herbal pieces reached 26.25%, leading the growth of the whole industry. Its retail market sales in 20 16 increased by 17.7% year-on-year to 2365438+32 million yuan, which is the fastest growing category of retail pharmacies.
Number of Chinese herbal pieces production enterprises 2006-20 15
The market share of Chinese herbal pieces is 20 15.
Due to the rapid growth and policy inclination, the concentration of the decoction pieces industry is extremely low. As the absolute leader in the market of Chinese herbal pieces, the company's revenue of Chinese herbal pieces in 20 17 years reached 61580,000 yuan, accounting for less than 3% of the market. There is no barrier to patent protection in the Chinese herbal pieces market. There are more than 1000 manufacturers, but most of them are small and medium-sized enterprises, with a scale of only one million to ten million. A market lacking patent technology protection. In the long run, we must win by product quality and channels. We estimate that the next 5- 10 years will be a period of industry reshuffle and overall concentration improvement.
The prescription flow of smart pharmacies has increased rapidly.
On June 20 15, the company cooperated with Guangdong Provincial Hospital of Traditional Chinese Medicine to launch "Smart Pharmacy" in Guangzhou. Since its launch, the business has grown rapidly and has been fully promoted in Guangzhou, Shenzhen, Beijing, Chengdu, Kunming and Puning. It has established long-term cooperative relations with more than 2,000 medical institutions and about 200,000 pharmacies, including Guangdong Provincial Hospital of Traditional Chinese Medicine, Shenzhen Hospital of Traditional Chinese Medicine, Guang 'anmen Hospital of Chinese Academy of Traditional Chinese Medicine, Beijing Hospital of Traditional Chinese Medicine, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine and Kunming Hospital of Traditional Chinese Medicine. The daily maximum number of prescriptions is 26,000, and 3.8 million prescriptions have been processed, serving more than 25,000 outpatients and about 1.35 million patients. In the future, the company will increase capital investment in "smart pharmacies", comprehensively and rapidly promote the implementation of "smart pharmacies" in various places, and actively start the construction of central pharmacies in Guiyang, Chongqing, Xiamen, Meihekou and other cities, and gradually form central pharmacies in urban agglomerations, maintain the first-Mover advantage, and quickly form the company's leading position in the field of mobile medical services.
Since 20 15, the cooperation agreement between Kangmei Medicine and local governments on smart pharmacies.
Smart pharmacies have blossomed all over the country in less than three years, and the business increase is very obvious. It is expected that with the acceleration of the company's investment and market development, the process of Kangmei Smart Pharmacy will be further accelerated. The company established Chengdu Kangmei Wisdom Pharmacy Co., Ltd. in February 20 17, and established Kangmei Wisdom Pharmacy (Yunnan) Co., Ltd. in June 20 17, respectively, and entered Sichuan and Yunnan markets, but the project expansion failed. Subsequently, according to the strategic cooperation agreements between the company and Chongqing (Chongqing: as of March 3, 20654381,the boiling point center of smart pharmacy has entered the construction stage, and other projects are being actively promoted), Guiyang, Gansu and other provinces and cities, the company will carry out smart pharmacy business in more provinces and cities, bringing considerable incremental market and great potential.
Layout of Kangmei Pharmaceutical Traditional Chinese Medicine Pieces Base
Kangmei Pharmaceutical has the largest production capacity of Chinese herbal pieces in China. At present, there are1/kloc-0 pieces of Chinese herbal pieces production lines that have been put into use and under construction in Guangdong, Beijing, Shanghai, Sichuan, Jilin, Anhui and Gansu, with a designed production capacity of about 54,000 tons. The project progress of Shanghai Traditional Chinese Medicine Pieces Factory has reached 90%. After the recent production, the total production capacity will reach 60,000 tons, which can support nearly 60,000 tons at full capacity. At the same time, on 20 16, the company started the project of 6000 tons of formula granules in Puning City, Guangdong Province, and it is expected that the production capacity will be gradually released in the next two to three years.
Statistics of market capacity items of traditional Chinese medicine formula granules
2065438+March, 2006 1 day, the public consultation on the Administrative Measures for Formulated Granules of Traditional Chinese Medicine (Draft for Comment) ended. At present, the production qualification of formula granules is gradually being liberalized. According to the latest announcement, the company has been approved as a pilot enterprise of traditional Chinese medicine formula granules in Guangdong Province, and is in the pilot scale-up and listing preparation stage of 202 varieties of traditional Chinese medicine formula granules. In addition, the original base of the company has a large output elasticity. If the market expands smoothly, the production capacity of two shifts can be greatly increased to ensure sufficient supply. The 6,000-ton capacity project that the company has built has been put into production at any time. Once listed, the company will use powerful channels such as smart pharmacies to sell quickly and in large quantities. Followed by medical device business, medical business, finance and valuation analysis.